An interventional study of AI-stethoscope in Heart Failure, Heart Valve Diseases and Atrial Fibrillation, sponsored by Imperial College London. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Imperial College London · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Heart Failure by Imperial College London — 7 open to participants now, 8 under way, none of them phase 3. Heart Failure · Imperial College London.
Among the 29 studies in Heart Failure by Imperial College London, this one is the 3rd largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2023, is one of 11 with no phase, and was the 24th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →7 of the 29 studies in Heart Failure by Imperial College London are open now, in 1 country. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
Imperial College London · Sites in United Kingdom
Ages 18–90
Imperial College London · Sites in United Kingdom
Ages 18+
Imperial College London · Sites in United Kingdom
Ages 18–85
Imperial College London · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 1
First in 2006; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 55 across the 18 interventional studies, 100 across the 11 observational. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
1 of the studies in Heart Failure by Imperial College London that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07057466Imperial College LondonProspective Evaluation of AI-ECG for SHD Detection | 2027-05-03 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Heart Failure by Imperial College London, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Heart failure (HF) is a condition in which the heart cannot pump blood adequately. It is increasingly common, consumes 4% of the UK National Health Service (NHS) budget and is deadlier than most cancers. Early diagnosis and treatment of HF improves quality of life and survival. Unacceptably, 80% of patients have their HF diagnosed only when very unwell, requiring an emergency hospital admission, with worse survival and higher treatment costs to the NHS. This is largely because General Practitioners (GPs) have no easy-to-use tools to check for suspected HF, with patients having to rely on a long and rarely completed diagnostic pathway involving blood tests and hospital assessment.
The investigators have previously demonstrated that an artificial intelligence-enabled stethoscope (AI-stethoscope) can detect HF in 15 seconds with 92% accuracy (regardless of age, gender or ethnicity) - even before patients develop symptoms. While the GP uses the stethoscope, it records the heart sounds and electrical activity, and uses inbuilt artificial intelligence to detect HF.
The goal of this clinical trial is to determine the clinical and cost-effectiveness of providing primary care teams with the AI-stethoscope for the detection of heart failure. The main questions it aims to answer are if provision of the AI-stethoscope:
200 primary care practices across North West London and North Wales, UK, will be recruited to a cluster randomised controlled trial, meaning half of the primary care practices will be randomly assigned to have AI-stethoscopes for use in direct clinical care, and half will not. Researchers will compare clinical and cost outcomes between the groups.
Triple Cardiovascular Disease Detection with Artificial Intelligence-enabled Stethoscope (TRICORDER) is an open label, cluster randomised controlled trial. The aim is to determine whether use of an artificial intelligence-enabled stethoscope (AI-stethoscope) in UK Primary Care improves community-based detection of heart failure (HF), compared with usual care. 200 primary care practices in North West London (UK) will be randomised to receive the AI-stethoscope (intervention arm) or continue with usual care (control arm). The intervention arm will use the AI-stethoscope in routine clinical practice. Outcomes will be measured using pooled primary and secondary care clinical and cost-data, as well as clinician questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Receive 3-6 AI-stethoscopes (Eko DUO, Eko Health Inc, CA, USA) including artificial intelligence software for detection of: 1. Reduced left ventricular ejection fraction \<40% 2. Atrial fibrillation 3. Cardiac murmurs
Device: AI-stethoscope
Usual care
Clinicians at practices in the intervention arm will be provided with one session of in-person training in use of the AI-stethoscope within 2 weeks of randomisation, including 1. Delivery and setup 2. Smartphone app installation and login 3. Pairing of all clinician smartphones with all AI-stethoscopes in the same practice 4. Demo of patient examination The AI-stethoscope will be used within its CE/UKCA-marked intended purpose. The clinical guidelines for use have been agreed by the NHS North West London Integrated Care System and Betsi Cadwaladr University Health Board Cardiovascular Executive Groups. Patients will be examined with the AI-stethoscope in accordance with these guidelines, and/or where stethoscope examination is deemed clinically appropriate. Patients will provide verbal consent for examination with the AI-stethoscope as per any physical examination performed by healthcare professionals for direct care, in accordance with UK law and General Medical Council guidelines.
Also known as: Eko DUO, Eko Core 500, Eko EAS
Incidence of heart failure (co-primary)
Difference in incidence of coded new diagnoses of heart failure (HF)
Time frame: 24 months
Ratio of route to diagnosis of heart failure (co-primary) between emergency and community-based pathways
Difference in ratio of the incidence of coded diagnoses of HF via hospital admission-based versus community-based pathways.
Time frame: 24 months
Incidence of atrial fibrillation
New coded diagnoses of atrial fibrillation (AF)
Time frame: 24 months
Incidence of valvular heart disease
New coded diagnoses of valvular heart disease (VHD)
Time frame: 24 months
Cost-consequence (AF)
Cost-consequence analysis (form of health economic evaluation) for diagnosis of atrial fibrillation, stratified by route to diagnosis. Presented in pounds sterling.
Time frame: 24 months
Cost-consequence (HFrEF)
Cost-consequence analysis (form of health economic evaluation) for diagnosis of HFrEF, stratified by route to diagnosis. Presented in pounds sterling.
Time frame: 24 months
Cost-consequence (VHD)
Cost-consequence analysis (form of health economic evaluation) for diagnosis of VHD, stratified by route to diagnosis. Presented in pounds sterling.
Time frame: 24 months
Health service utilisation
Health service utilisation for diagnostics e.g. rates of request for echocardiography, electrocardiography, primary care appointments. Collected from NHS organisation business intelligence repositories and UK Trusted Research Environments.
Time frame: 24 months
Proportion of patients prescribed guideline-directed medical therapy
Proportion of patients prescribedguideline-directed medical therapy (HF, AF, VHD)
Time frame: 24 months
Device therapy
New implantation of cardiac resynchronisation therapy (CRT) and/or implantable cardioverter-defibrillator (ICD)
Time frame: 24 months
Uptake and utilisation
Differential rates of uptake and utilisation of AI-stethoscope in primary care
Time frame: 24 months
Determinants of uptake and utilisation
Determinants of utilisation of AI-stethoscope in primary care (clinician questionnaires)
Time frame: 24 months
Patient quality of life
Healthy Days at Home (patient-level analysis)
Time frame: 24 months
Sensitivity analysis
Patient-level sensitivity analyses will be performed for patients with abnormal Eko DUO predictions for HF, to identify direct associations between AI-stethoscope predictions and specific diagnostic codes for HF, AF and VHD
Time frame: 24 months
Plan to share: No
Started Oct 2023 (actual). Primary completion is estimated for Jun 2028, 55 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 55 months is above that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2025 → Jun 2028 and completion Dec 2025 → Jun 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.